Key result
Exosomal miR-21-5p enhances human engineered cardiac tissue contractility and calcium handling gene expression.
miR-21-5p is a key mediator of the procontractile paracrine effects of human mesenchymal stem cells on cardiac tissue, representing a specific molecular target for optimizing stem cell-based cardiotherapies.
Answers are grounded in this paper and cite their sources.
miR-21-5p may enhance contractility in engineered cardiac tissue; hypothesis-generating for miRNA-targeted stem cell therapies pending in vivo confirmation.
RATIONALE: The promising clinical benefits of delivering human mesenchymal stem cells (hMSCs) for treating heart disease warrant a better understanding of underlying mechanisms of action. hMSC exosomes increase myocardial contractility; however, the exosomal cargo responsible for these effects remains unresolved. OBJECTIVE: This study aims to identify lead cardioactive hMSC exosomal microRNAs to provide a mechanistic basis for optimizing future stem cell-based cardiotherapies. METHODS AND RESULTS: Integrating systems biology and human engineered cardiac tissue (hECT) technologies, partial least squares regression analysis of exosomal microRNA profiling data predicted microRNA-21-5p (miR-21-5p) levels positively correlate with contractile force and calcium handling gene expression responses in hECTs treated with conditioned media from multiple cell types. Furthermore, miR-21-5p levels were significantly elevated in hECTs treated with the exosome-enriched fraction of the hMSC secretome (hMSC-exo) versus untreated controls. This motivated experimentally testing the human-specific role of miR-21-5p in hMSC-exo-mediated increases of cardiac tissue contractility. Treating hECTs with miR-21-5p alone was sufficient to recapitulate effects observed with hMSC-exo on hECT developed force and expression of associated calcium handling genes (eg, SERCA2a and L-type calcium channel). Conversely, knockdown of miR-21-5p in hMSCs significantly diminished exosomal procontractile and associated calcium handling gene expression effects on hECTs. Western blots supported miR-21-5p effects on calcium handling gene expression at the protein level, corresponding to significantly increased calcium transient amplitude and decreased decay time constant in comparison to miR-scramble control. Mechanistically, cotreating with miR-21-5p and LY294002, a PI3K inhibitor, suppressed these effects. Finally, mathematical simulations predicted the translational capacity for miR-21-5p treatment to restore calcium handling in mature ischemic adult human cardiomyocytes. CONCLUSIONS: miR-21-5p plays a key role in hMSC-exo-mediated effects on cardiac contractility and calcium handling, likely via PI3K signaling. These findings may open new avenues of research to harness the role of miR-21-5p in optimizing future stem cell-based cardiotherapies.
No takes yet. Share an insight, caveat, or question.
Mayourian et al. (2018) studied Ischemic and nonischemic cardiomyopathies (in vitro/preclinical model). miR-21-5p (human mesenchymal stem cell exosomes) vs. Serum-free defined media or miR-scramble control was evaluated on Cardiac tissue contractility (developed force) (p=<0.05). miR-21-5p significantly increased human engineered cardiac tissue contractile force and calcium handling gene expression, mediating the paracrine procontractile effects of human mesenchymal stem cell exosomes.
Synapse has enriched 10 related papers. Consider them for comparative context: